Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition

Rhea-AI Summary

Autolus Therapeutics (Nasdaq: AUTL) will hold a conference call on December 13, 2021, at 8:00 am ET to discuss data presented at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place December 11-14. This call reflects a timing change from the previous announcement. The call will include a webcast with accompanying slides available on the company's website. A replay of the call will be accessible for one week after.

Positive

• Management is engaging with investors through a scheduled call to discuss ASH data, indicating transparency and involvement.
• The company showcases its presence at a significant industry event, which may enhance its visibility and credibility.

Negative

• None.

Conference Call and Webcast to be held on Monday, December 13, 2021 at 8:00 am ET / 1:00 pm GMT

LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it will hold a conference call to discuss the data being presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, being held between December 11-14, 2021. Note this is a change to the timing announced previously.

New timing of investor call

Management will host a conference call and webcast on Monday, December 13, 2021, at 8:00 am ET/1:00 pm GMT to discuss the ASH data. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus’ website.

Conference Dial in:

• United States and Canada (866) 679-5407
• International (409) 217-8320
• Conference ID 31044873
  

Replay:
A replay will be available for one week following the call

• United States and Canada (855) 859-2056
• International (404) 537-3406
• Conference ID 31044873
  

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Business Strategy and Planning
+44 (0) 7587 372 619 
l.crabtree@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

FAQ

What is the date and time of the Autolus Therapeutics conference call?

The conference call is scheduled for December 13, 2021, at 8:00 am ET.

Where will the data from the ASH Annual Meeting be discussed by Autolus?

The data will be discussed during a conference call accessible via the company's website.

How can investors listen to the Autolus Therapeutics conference call?

Investors can listen through a webcast available on Autolus' events section of their website.

Is there a replay available for the Autolus conference call?

Yes, a replay will be available for one week following the call.

What significant event is Autolus Therapeutics participating in?

Autolus is participating in the 63rd American Society of Hematology (ASH) Annual Meeting.